Skip to main content

Clinical trial DS8201-A-U303

A phase 3, multicenter, randomized, open-label, active-controlled trial of DS-8201a, an anti-HER2-antibody drug conjugate (ADC), versus treatment of Physician's choice for HER2-low, HR-positive, unresectable and/or metastatic breast cancer subjects (DS8201-A-U303)

Cancers
Organ Breast
Trial status Trial closed for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Daiichi
EudraCT Identifier 2018-003069-33
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03734029
Inclusion criteria HER2 low (+ or ++)/ER+ or ER-. Metastatic
Last update